Marginal versus conditional rate estimation for count and recurrent event data with an estimand framework

Count and recurrent event endpoints are common key efficacy endpoints in clinical research. For example, in clinical research of pulmonary diseases such as chronic obstructive pulmonary disease (COPD) or asthma, the reduction of the occurrence of a recurrent event, pulmonary exacerbation (PEx) cause...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Contemporary clinical trials Jg. 138; S. 107414
Hauptverfasser: Conner, Sarah C., Zhou, Yijie, Xu, Tu
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Elsevier Inc 01.03.2024
Schlagworte:
Asthma - drug therapy
Asthma - epidemiology
Cardiovascular
Collapsibility
Computer Simulation
Estimand framework
G-computation
Generalized linear model
Hematology, Oncology, and Palliative Medicine
Humans
Marginal/conditional rate
Models, Statistical
Pulmonary Disease, Chronic Obstructive - epidemiology
Recurrent events
Research Design
Estimand framework
G-computation
Generalized linear model
Marginal/conditional rate
Collapsibility
Recurrent events
ISSN:1551-7144, 1559-2030, 1559-2030
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Count and recurrent event endpoints are common key efficacy endpoints in clinical research. For example, in clinical research of pulmonary diseases such as chronic obstructive pulmonary disease (COPD) or asthma, the reduction of the occurrence of a recurrent event, pulmonary exacerbation (PEx) caused by acute respiratory symptoms, is often used to measure the treatment effect. The occurrence of PEx is often analyzed with nonlinear models, such as Poisson regression or Negative Binomial regression. It is observed that model-estimated within-group PEx rates are often lower than the descriptive statistics of within-group PEx rates. Motivated by this observation, we explore their relationship mathematically and demonstrate that it is due to the difference between conditional PEx rates and population-level PEx rates (marginal rates). Our findings corroborate the recent FDA guidance (2023) [1], which discusses considerations for covariate adjustment in nonlinear models, and that conditional or subgroup treatment effects with covariate adjustment may differ from marginal treatment effects. In this article, we demonstrate how covariate adjustment impacts the estimation of event rates and rate ratios with both closed form and simulation studies. Additionally, following the ICH E9 addendum on the estimand framework [2], we discuss the estimand framework for count and recurrent event data.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1551-7144
1559-2030
1559-2030
DOI:10.1016/j.cct.2023.107414